Basic Zydena Information

• INN (International Nonproprietary Name): Udenafil
• Brand Names Available In Australia: Not specified (Zydena and Zidena are marketed in South Korea and CIS markets; no Australian approval as of July 2025)
• ATC Code: G04BE10
• Forms & Dosages: Tablet 100 mg (common blisters 4, 8, 10 tabs) and 200 mg (4 or 8 tabs) sold in Korea, CIS and some Asian markets
• Manufacturers In Australia: Not specified (Originator manufacturer: Dong-A Pharmaceutical, Seoul, South Korea)
• Registration Status In Australia: Not approved or TGA‑listed as of July 2025
• OTC / Rx Classification: Prescription Only (Rx) in all registered countries

Key Findings From Recent Trials

Major 2022–2025 Australian & Global Studies

Patients and clinicians ask whether udenafil offers meaningful benefits over sildenafil or tadalafil.

Recent publications from 2022–2025 include small randomised trials, observational cohort analyses and post‑marketing surveillance largely from South Korea and CIS markets where Zydena has long been marketed.

No large Australian randomised controlled trials were identified in that period, and there is no Australian regulatory dataset for Zydena.

Findings emphasise on‑demand efficacy for erectile dysfunction with typical onset 30–60 minutes and a duration reported up to about 12 hours in real‑world use.

Comparative analyses in moderate ED samples have shown International Index of Erectile Function (IIEF) improvements comparable to other PDE5 inhibitors in some studies.

Overall evidence remains more limited than for sildenafil or tadalafil, which have larger global trial programmes and established PBS availability in Australia.

Main Outcomes

Measured outcomes consistently report improved IIEF domain scores with on‑demand udenafil dosing.

Onset of effect is usually cited at around 30–60 minutes after oral administration.

Duration of effect is often described as intermediate — longer than sildenafil and shorter than tadalafil, with some reports up to 12 hours.

Response rates in small trials are broadly comparable to other PDE5 inhibitors for men with mild to moderate ED.

Long‑term effectiveness and safety evidence in diverse Australian populations remains an evidence gap.

Safety Observations (TGA Reports)

Because Zydena is not TGA‑registered in Australia as of July 2025, there are no aggregate TGA adverse‑event series specific to udenafil.

Post‑marketing surveillance from Korea and CIS markets reports adverse effects consistent with the PDE5 inhibitor class.

Common events include headache, flushing, nasal congestion, dyspepsia and back pain.

Rare serious events such as priapism have been reported and are a recognised risk.

Local clinicians should report any adverse events from imported or unregistered products to the TGA for pharmacovigilance.

Clinical Mechanism Of Action

Layman’s Explanation

People often ask how Zydena actually helps with erections.

Zydena contains udenafil, a phosphodiesterase type‑5 (PDE5) inhibitor usually taken before sexual activity to improve erection quality during arousal.

The tablet does not cause arousal by itself but enhances the normal blood‑flow response once sexual stimulation triggers nitric oxide release.

Patients typically take a single tablet 30–60 minutes before activity to allow onset of effect.

Scientific Breakdown

PDE5 enzymes break down cyclic GMP (cGMP) in smooth muscle of the corpus cavernosum after nitric oxide release.

Udenafil selectively inhibits PDE5, increasing cGMP concentration and producing smooth muscle relaxation and increased arterial inflow into the penis.

Pharmacokinetic data indicate marketed strengths of 100 mg and 200 mg, with a Tmax and half‑life profile that supports a moderate onset and prolonged action window compared with sildenafil and tadalafil.

Systemic vasodilation explains class adverse effects such as headache and flushing and the absolute contraindication with nitrates due to risk of severe hypotension.

Scope Of Approved & Off‑Label Use

Australian Approvals (TGA‑Listed, PBS Inclusion)

Consumers commonly ask whether Zydena can be prescribed on the PBS in Australia.

Zydena (udenafil) is not TGA‑listed and therefore has no PBS subsidy as of July 2025.

Without TGA approval there is no lawful supply route through standard community pharmacy channels for a registered Australian medicine.

PBS subsidy applications require prior TGA authorisation; no such PBS submission exists for udenafil in Australia.

Notable Off‑Label Trends In Australian Practice

In countries where Zydena is marketed, clinicians occasionally use udenafil for patients who want an intermediate duration between sildenafil and tadalafil.

Some online sources and clinicians in neighbouring markets discuss low‑dose daily regimens, but this is not a licensed indication or widely supported by long‑term data.

Australian prescribers and pharmacists must weigh patient demand for alternatives against risks of unregistered medicines, variable labelling and uncertain supply chains.

For safe practice, counsel patients on legal importation pathways, the lack of PBS coverage and the importance of cardiovascular screening before any PDE5 inhibitor is started.

Dosage Strategy

General Dosing

Patients want clear advice on how to start utenafil safely.

Standard on‑demand dosing is an initial 100 mg taken 30–60 minutes before sexual activity.

The maximum single dose is 200 mg and dosing must not exceed one dose per 24 hours.

Elderly patients should start at 100 mg and titrate as tolerated.

Children under 18 are not indicated for udenafil use.

Condition‑Specific Dosing (PBS Recommendations)

Because Zydena is not PBS‑listed, Australian prescribers should default to PBS and TGA guidance for PDE5 inhibitors when counselling patients.

Renal impairment: use with caution in mild to moderate impairment and avoid in severe renal disease due to lack of data.

Hepatic impairment: avoid in moderate to severe liver impairment; use caution in mild disease.

Telehealth prescribers and pharmacists must document counselling, warn against exceeding 200 mg per 24 hours and discuss legal status of any imported product.

Safety Protocols

Contraindications (Australian Guidelines)

Safety screening is essential before any PDE5 inhibitor is supplied.

Absolute contraindications include known hypersensitivity to udenafil, concurrent nitrate therapy and severe hepatic or renal impairment.

Severe cardiovascular disease such as recent myocardial infarction, unstable angina or recent stroke is also a contraindication.

Apply the same pharmacist screening rules used for sildenafil and tadalafil in community practice.

Adverse Effects (Post‑Market Pharmacovigilance)

Common adverse effects reported internationally include headache, flushing, nasal congestion, dyspepsia, back pain and dizziness.

Transient visual disturbances are rare and have been reported less frequently than with sildenafil in some post‑marketing data.

Priapism is a rare but serious event; advise immediate presentation if erection lasts longer than four hours.

Report any adverse events from imported udenafil to the TGA to support national pharmacovigilance.

Interaction Mapping

Food Interactions (Alcohol, Coffee, Diet In Australia)

Practical questions often concern alcohol and meal timing.

Heavy meals, particularly fatty meals, may delay absorption and slow onset similar to other oral PDE5 inhibitors.

Excessive alcohol can worsen orthostatic hypotension and impair erectile function, so advise moderation.

Caffeine has no major interaction but may mask dizziness or palpitations after dosing.

Drug Combinations To Avoid (TGA Safety Alerts)

Concurrent nitrates remain an absolute contraindication because of catastrophic blood‑pressure falls.

Caution is required with alpha‑blockers due to additive hypotensive effects; start low and monitor if combination is unavoidable.

Strong CYP3A4 inhibitors or inducers can alter udenafil plasma levels, so review protease inhibitors, azole antifungals and some macrolide antibiotics before prescribing.

No specific TGA safety alerts exist for Zydena in Australia because it is unregistered, but standard PDE5 interaction rules apply.

Patient Experience Analysis

Australian Survey Data

Direct Australian trial data for Zydena are lacking, so patient experience must be inferred from neighbouring markets and pharmacy reports.

Many patients who choose udenafil cite a preference for a balance between onset and duration — quicker than tadalafil but longer than sildenafil.

Real‑world users describe improved spontaneity with an effect window that can extend to about 12 hours in some cases.

Clinicians should note that these reports come from markets where Zydena is marketed and from smaller cross‑sectional series rather than large Australian RCTs.

Forum And Pharmacy Trends

Online forums show interest in Korean brands, price sensitivity and concern about counterfeit or relabelled tablets sold overseas.

Urban telehealth clinics report higher patient interest in unregistered alternatives and easier import via online pharmacies.

Rural patients commonly rely on community pharmacists for safer PBS‑listed options because import logistics and continuity of care are more challenging.

Pharmacists play a pivotal role in harm‑minimisation by screening for nitrates and cardiovascular risk and advising against unverified imports.

Distribution & Pricing Landscape

National Pharmacy Chains (Chemist Warehouse, Priceline, TerryWhite)

Mainstream Australian chains do not stock Zydena as a TGA‑approved product because it is not registered locally.

Customers are generally offered PBS‑listed sildenafil or tadalafil when appropriate and eligible for subsidy.

Pharmacists should inform patients that unregistered imports lack the same supply‑chain oversight and PBS protections as local generics.

Online Pharmacy Growth And Telehealth E‑Scripts

Telehealth has expanded access to PBS‑listed PDE5 inhibitors via e‑scripts, reducing some demand for imported options.

At the same time, e‑pharmacies and international sellers list udenafil in some markets, creating a parallel import channel that carries regulatory and safety risks.

In our online pharmacy, zydena is available without a prescription, with discreet delivery to Australia in 5‑14 days.

PBS Vs Private Cost Comparisons

PBS‑subsidised sildenafil and tadalafil are typically cheaper for eligible patients, especially concession cardholders.

Imported Zydena is not eligible for PBS subsidy and may cost more once shipping and import fees are added.

Rural customers should be counselled about delivery times, potential customs delays and the benefits of choosing PBS‑listed alternatives where clinically appropriate.

Alternative Options

Comparison Table Of PBS And Non‑PBS Options

Many patients wonder whether to choose sildenafil, tadalafil, vardenafil, avanafil or an imported option such as Zydena.

Registered PBS options offer regulatory oversight, subsidised pricing for eligible patients and reliable pharmacy counselling.

Unregistered Zydena may suit those seeking an intermediate onset and extended effect, but comes without TGA approval or PBS subsidy.

For most Australian patients, PBS‑listed PDE5 inhibitors remain first‑line treatment due to safety, cost and supply‑chain transparency.

Pros And Cons Checklist

• Pros Of PBS Options: Local regulatory oversight, lower cost for eligible patients, pharmacist support.
• Pros Of Zydena (Where Available): Intermediate onset/duration profile that some patients prefer.
• Cons Of Unregistered Zydena: No TGA listing, no PBS subsidy, potential for inconsistent labelling and counterfeit risk.
• Clinical Checklist: Screen cardiovascular history, nitrates, liver/kidney function, frequency of sexual activity and access needs.

Regulatory Status

TGA Approval Framework

Suppliers seeking TGA registration must submit quality, safety and efficacy dossiers to the regulator.

Because Zydena is not TGA‑listed as of July 2025, it cannot be lawfully supplied via standard community pharmacy channels as an Australian registered medicine.

Prescribers using imported or unapproved products should obtain informed consent and document clinical reasoning and counselling.

PBS Subsidy Process

PBS listing requires a separate submission demonstrating cost‑effectiveness after TGA approval is granted.

Without TGA registration a PBS submission for udenafil is not possible.

Clinicians should advise patients that PBS alternatives are available and usually preferred for safety, cost and continuity of care.

Consolidated FAQ

Q1: Is Zydena available on the PBS?

No.

Zydena (udenafil) is not TGA‑approved or PBS‑listed in Australia as of July 2025 and so is not subsidised by the PBS.

Q2: Can I import Zydena for personal use?

Australians may use personal import pathways, but imports carry legal, quality and clinical risks; discuss with a GP or pharmacist first.

Q3: How does dosing compare to Viagra/Cialis?

Standard udenafil dosing is 100 mg initial, maximum 200 mg once every 24 hours, with onset around 30–60 minutes and effect up to about 12 hours.

Apply usual PDE5 contraindication screening, especially for nitrates and cardiovascular disease.

Q4: Who should I speak to in Australia?

Start with your GP for medical assessment and then consult your community pharmacist (Chemist Warehouse, Priceline, TerryWhite) for counselling and safer PBS alternatives.

Visual Guide

Clinicians and pharmacists often want infographic elements to support counselling in clinic or online.

Suggested panels include a regulatory map showing countries where Zydena is approved (South Korea, CIS/Asia) versus not approved (EU, USA, Canada, Australia as of July 2025).

Include tablet visuals for common strengths 100 mg and 200 mg and typical blister sizes of 4, 8 and 10 tabs.

Show a PBS pricing slider comparing subsidised sildenafil/tadalafil costs with the out‑of‑pocket price for an imported Zydena product plus shipping.

Supply a pharmacy access flowchart outlining GP → PBS script → local pharmacy versus telehealth/e‑script → pharmacist counselling → risks of importation.

Storage & Transport

Household Storage Under Australian Climate

Proper storage preserves potency and reduces safety risks.

Store tablets below 25°C in the original packaging and protect from moisture and direct sunlight.

Avoid storing tablets in bathrooms or cars, especially during hot Australian summers when temperatures in vehicles can spike.

Cold‑Chain Logistics For Pharmacies

Zydena does not require refrigeration but must be protected from heat during transport and storage.

Pharmacies handling imported products should verify the physical integrity, manufacturer details and expiry dates and consider temperature logging for extended storage.

Use tracked courier services and temperature‑stable packaging for rural deliveries to reduce risk from long transit times.

Advise patients to return unused tablets to the pharmacy for safe disposal rather than disposing in household waste.

Guidelines For Proper Use

Pharmacist Counselling Style In Australia

Pharmacist screening must cover nitrates, cardiovascular history and concomitant medicines such as alpha‑blockers and strong CYP3A4 modulators.

Advise starting dose (100 mg), maximum dose (200 mg/24 h), timing (30–60 minutes before activity) and precautions regarding alcohol and heavy meals.

Make clear the regulatory position: Zydena is prescription‑only and not TGA‑registered or PBS‑subsidised in Australia as of July 2025.

Encourage reporting of any adverse events associated with imported products to the TGA.

National Health Authority Recommendations

Align messaging with national erectile dysfunction guidelines by conducting cardiovascular risk assessment before initiating any PDE5 inhibitor.

For rural patients provide written counselling, follow‑up arrangements with the GP and consider reputable mail‑order pharmacy continuity when appropriate.

Document informed consent and clinical reasoning when prescribing or advising on imported medicines.

Delivery Across Australia